Yahoo · Aug 13, 2026
Guardian Pharmacy Services (GRDN) Q2 2026 Earnings Call Transcript
Adjusted EBITDA surged 19% despite IRA pricing headwinds and fuel cost pressures.
GR
NYSE · GRDN
Guardian Pharmacy Services, Inc.
Healthcare · Medical - Distribution
$37.93
Up+$0.45 (+1.20%)
Updated Aug 22, 2026, 7:12 PM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.98B
- P/E ratio
- 48.15
- Dividend yield
- 0.00%
- 52-week range
- $30.61 – $47.02
- Volume
- 396.48K
- Avg. volume
- 348.69K
Price performance
GRDN price history
1M range · 21 trading sessions · Daily adjusted prices
GRDN closed at $37.93 after 21 trading sessions, down 6.23% for the selected period.
- Last close
- $37.93
- Period change
- -6.23%
- Period low
- $37.48
- Period high
- $43.83
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $37.55 | $38.12 | $36.90 | $37.93 | 396.48K |
| Aug 20, 2026 | $37.51 | $37.995 | $37.24 | $37.48 | 214.91K |
| Aug 19, 2026 | $38.44 | $39.57 | $37.705 | $37.97 | 230.68K |
| Aug 18, 2026 | $37.93 | $38.8603 | $37.70 | $38.28 | 368.95K |
| Aug 17, 2026 | $38.34 | $38.775 | $37.53 | $38.00 | 459.46K |
| Aug 14, 2026 | $38.37 | $39.05 | $37.575 | $38.43 | 290.71K |
| Aug 13, 2026 | $39.08 | $39.51 | $37.7135 | $38.46 | 310.92K |
| Aug 12, 2026 | $40.00 | $40.00 | $38.44 | $38.58 | 364.8K |
| Aug 11, 2026 | $41.66 | $41.66 | $38.74 | $39.46 | 705.26K |
| Aug 10, 2026 | $43.45 | $44.13 | $40.99 | $41.47 | 454.69K |
| Aug 7, 2026 | $43.15 | $47.02 | $42.065 | $43.83 | 1.05M |
| Aug 6, 2026 | $40.49 | $40.695 | $39.15 | $39.47 | 283.18K |
| Aug 5, 2026 | $40.17 | $41.1099 | $40.17 | $40.50 | 164.37K |
| Aug 4, 2026 | $41.35 | $41.64 | $40.48 | $40.53 | 201.01K |
| Aug 3, 2026 | $39.88 | $40.94 | $39.88 | $40.81 | 246.98K |
| Jul 31, 2026 | $40.79 | $41.725 | $39.23 | $39.53 | 431.33K |
| Jul 30, 2026 | $41.23 | $41.92 | $40.2083 | $41.20 | 191.52K |
| Jul 29, 2026 | $41.76 | $43.2686 | $40.31 | $40.99 | 261.16K |
| Jul 28, 2026 | $42.14 | $42.14 | $41.21 | $41.86 | 201.09K |
| Jul 27, 2026 | $40.84 | $42.19 | $40.35 | $41.46 | 315.81K |
| Jul 24, 2026 | $40.06 | $40.55 | $39.30 | $40.45 | 251.61K |
Latest GRDN news
The latest Smart Investors Daily articles mentioning GRDN.
Stock researchCompany · Overview
GRDN research
Overview
Company profile and research snapshot.
Company profile
Guardian Pharmacy Services Inc is a differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing, and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs and BHFs. The operating segment derives its revenues through sales of pharmaceutical and medical products, and all revenues are derived solely in the United States.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $32.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | Oppenheimer | Outperform | — |
| Jun 17, 2026 | Truist Securities | Buy | — |
| Jun 17, 2026 | B of A Securities | Buy | — |
| May 7, 2026 | Oppenheimer | Outperform | — |
| Apr 27, 2026 | B of A Securities | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 9, 2026
Guardian Pharmacy Services (GRDN) As Strong Results And Higher Outlook Recast The Valuation Story
Why Guardian Pharmacy Services’ latest earnings matter for investors Guardian Pharmacy Services (GRDN) reported second quarter 2026 results on 6 August with higher net income versus a year earlier and updated full year guidance that points to higher expected revenue and adjusted EBITDA. Management linked the guidance change to underlying growth drivers, including mitigation of Inflation Reduction Act pricing pressures, recent acquisitions, new pharmacy openings, and a revised regional...
Yahoo · Aug 8, 2026
Why Guardian Pharmacy Services (GRDN) Is Up 10.9% After Raising 2026 Revenue Guidance And Expanding Footprint
In the past week, Guardian Pharmacy Services, Inc. reported second-quarter 2026 results showing sales of US$351.77 million and net income of US$21.87 million, and it raised full-year 2026 revenue guidance to US$1.43 billion–US$1.45 billion while outlining ongoing expansion through acquisitions and new pharmacy openings. The combination of strong year-over-year profit growth, consistent earnings beats versus analyst estimates, and continued footprint expansion despite pricing pressure under...
Yahoo · Aug 8, 2026
Guardian Pharmacy Services Q2 Earnings Call Highlights
Guardian Pharmacy Services (NYSE:GRDN) reported second-quarter revenue growth of 2% year over year to $351.2 million, while adjusted EBITDA increased 19% to $29.7 million, as the company said it continued to offset profitability pressure from Inflation Reduction Act-related drug pricing reductions.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
